/
© 2026 RiffOn. All rights reserved.

Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

  1. OncLive® On Air
  2. S18 Ep43: Neoadjuvant Immunotherapy and Short Treatment Courses Drive Paradigm Shifts in CRC Management
S18 Ep43: Neoadjuvant Immunotherapy and Short Treatment Courses Drive Paradigm Shifts in CRC Management

S18 Ep43: Neoadjuvant Immunotherapy and Short Treatment Courses Drive Paradigm Shifts in CRC Management

OncLive® On Air · Sep 25, 2026

Neoadjuvant immunotherapy is revolutionizing CRC treatment, with studies like NICHE2 and NEST showing promise for both MSI-high and MSS tumors.

Goal of Neoadjuvant IO in Colon Cancer Is Curing Micro-Metastases, Not Shrinkage

Unlike in rectal cancer where pre-surgical shrinkage is key, the primary objective of neoadjuvant immunotherapy in operable colon cancer is to activate a systemic immune response. This targets and eliminates unseen micro-metastases, the true cause of recurrence, thereby increasing the overall cure rate.

S18 Ep43: Neoadjuvant Immunotherapy and Short Treatment Courses Drive Paradigm Shifts in CRC Management thumbnail

S18 Ep43: Neoadjuvant Immunotherapy and Short Treatment Courses Drive Paradigm Shifts in CRC Management

OncLive® On Air·2 months ago

Colorectal Cancer Is Now the Leading Cancer Killer for Americans Under 50

There is an alarming and unexplained rise in early-onset colorectal cancer, making it the top cause of cancer death for individuals under 50. These younger patients often present with more advanced, aggressive disease and have poorer outcomes despite receiving aggressive treatments.

S18 Ep43: Neoadjuvant Immunotherapy and Short Treatment Courses Drive Paradigm Shifts in CRC Management thumbnail

S18 Ep43: Neoadjuvant Immunotherapy and Short Treatment Courses Drive Paradigm Shifts in CRC Management

OncLive® On Air·2 months ago

Circulating Tumor DNA Could Become a Surrogate Endpoint to Speed Drug Approvals

Measuring circulating tumor DNA (ctDNA) to detect minimal residual disease (MRD) after treatment is a powerful predictor of recurrence. This biomarker could be used as a surrogate endpoint in clinical trials, allowing for accelerated drug approvals based on early data rather than waiting years for survival outcomes.

S18 Ep43: Neoadjuvant Immunotherapy and Short Treatment Courses Drive Paradigm Shifts in CRC Management thumbnail

S18 Ep43: Neoadjuvant Immunotherapy and Short Treatment Courses Drive Paradigm Shifts in CRC Management

OncLive® On Air·2 months ago

Neoadjuvant Immunotherapy Flips CRC Treatment, Making Surgery the Adjuvant Step

The traditional CRC treatment path (chemo-surgery-chemo) is being upended. New data shows giving immunotherapy before surgery can be so effective that the surgery itself becomes the "adjuvant" or follow-up treatment, representing a major paradigm shift.

S18 Ep43: Neoadjuvant Immunotherapy and Short Treatment Courses Drive Paradigm Shifts in CRC Management thumbnail

S18 Ep43: Neoadjuvant Immunotherapy and Short Treatment Courses Drive Paradigm Shifts in CRC Management

OncLive® On Air·2 months ago

NEST Study Shows Novel Immunotherapy Can Activate "Cold" MSS Colon Cancers

The NEST study demonstrated that a novel FC-enhanced CTLA-4 inhibitor can induce immune responses in microsatellite stable (MSS) colon cancer. This is the most common subtype, typically resistant to immunotherapy, opening a new treatment avenue for the majority of CRC patients.

S18 Ep43: Neoadjuvant Immunotherapy and Short Treatment Courses Drive Paradigm Shifts in CRC Management thumbnail

S18 Ep43: Neoadjuvant Immunotherapy and Short Treatment Courses Drive Paradigm Shifts in CRC Management

OncLive® On Air·2 months ago

MSI-High CRC Responds to Immunotherapy Due to a Faulty Genetic 'Autocorrect'

Mismatch repair deficient (dMMR/MSI-H) tumors respond to immunotherapy because their DNA repair mechanism—an "autocorrect" for genetic code—is broken. This creates over 25 times more mutations, making the cancer highly visible and attackable by the immune system.

S18 Ep43: Neoadjuvant Immunotherapy and Short Treatment Courses Drive Paradigm Shifts in CRC Management thumbnail

S18 Ep43: Neoadjuvant Immunotherapy and Short Treatment Courses Drive Paradigm Shifts in CRC Management

OncLive® On Air·2 months ago

Pre-Surgery Immunotherapy Uses the Tumor as an In-Situ Anti-Cancer Vaccine

Administering immunotherapy while the primary tumor and lymph nodes are intact allows them to act as an "in-situ vaccine." This generates a more diverse and powerful systemic immune response against cancer cells throughout the body compared to treating after surgical removal of these antigenic sources.

S18 Ep43: Neoadjuvant Immunotherapy and Short Treatment Courses Drive Paradigm Shifts in CRC Management thumbnail

S18 Ep43: Neoadjuvant Immunotherapy and Short Treatment Courses Drive Paradigm Shifts in CRC Management

OncLive® On Air·2 months ago